Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage
biopharmaceutical company developing nucleotide therapeutics for
patients with cancer and orphan diseases, today announced that it will
be added to the Russell 3000® and Russell 2000® Indexes when Russell
Investments reconstitutes its comprehensive set of U.S. and global
equity indexes on Friday, June 27, 2014, according to a preliminary list
of additions posted on June 13, 2014 on www.russell.com/indexes.
Annual reconstitution of Russell's U.S. indexes captures the 4,000
largest U.S. stocks as of the end of May, ranking them by total market
capitalization. Membership in the Russell 3000, which remains in place
for one year, means Idera’s automatic inclusion in the small-cap Russell
2000 Index as well as the appropriate growth and value style indexes.
The Russell 3000 also serves as the U.S. component to the Russell Global
Index.
Russell indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for both passive and active
investment strategies. Approximately $5.2 trillion in assets are
benchmarked to the Russell Indexes.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals is a
clinical-stage biopharmaceutical company developing a novel therapeutic
approach for the treatment of genetically defined forms of B-cell
lymphoma and orphan autoimmune diseases. Idera’s proprietary technology
involves creating novel nucleic acid therapeutics designed to inhibit
over-activation of Toll-like Receptors (TLRs). In addition to its TLR
programs, Idera is developing gene silencing oligonucleotides (GSOs)
that it has created using its proprietary technology to inhibit the
production of disease-associated proteins by targeting RNA.
Copyright Business Wire 2014